No PHI stored HIPAA-compliant by design SOC2 in progress
Oncology · Denial Defense

Oncology prior auths are denied at 3x the rate of other specialties

Chemotherapy, immunotherapy, and targeted therapy require prior authorization from every major payer — and denials delay treatment while your staff spends hours on appeals that should never have been necessary.

3x
denial rate vs avg specialty
89%
of oncology denials are overturned on appeal
$214K
avg oncology practice writes off/year

High-denial oncology drugs — what PriorZap tracks

Drug / ClassCommon Denial ReasonPriorZap Prevention
Keytruda (pembrolizumab)Missing PD-L1 test documentationFlags missing biomarker at order entry
Opdivo (nivolumab)Step therapy — must try older agent firstDocuments contraindications automatically
Ibrance (palbociclib)Diagnosis code doesn't match payer criteriaValidates ICD-10 alignment before submission
Revlimid (lenalidomide)REMS program documentation incompleteREMS checklist embedded in CDS alert
Herceptin (trastuzumab)HER2 status not documented in claimPulls HER2 result from FHIR record
Avastin (bevacizumab)Not first-line for stated diagnosisLine of therapy automatically documented

PriorZap for Oncology Practices

Deploy at the point of prescribing inside Epic or Oracle Health. Every chemotherapy order triggers an automated prior-auth check before it leaves your EHR.